Business Wire

ERYTECH to Present at Morgan Stanley Global Healthcare Conference

Jaa

Regulatory News:

ERYTECH Pharma (Paris:ERYP) (ADR: EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15 th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017 at the Grand Hyatt Hotel in New York City.

Conference Details:

  • Conference: Morgan Stanley Global Healthcare Conference
  • Date: Wednesday, September 13th, 2017
  • Time: 2:10 p.m. EST

Investors attending the conference who would like to schedule a one-on-one meeting with management may do so by contacting their Morgan Stanley representative or by contacting ERYTECH’s Director of Investor Relations, Naomi Eichenbaum at +1 917-312-5151 or naomi.eichenbaum@erytech.com.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.

The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multiagent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.

Eryaspase achieved positive efficacy and safety results in a Phase 2 study in elderly patients with ALL, and a Phase 2/3 study in children and adults with relapsed or refractory ALL. ERYTECH believes that the positive results of its Phase 2b clinical study in second-line metastatic pancreatic cancer are significant indicators of eryaspase as a potential treatment approach in solid tumors. ERYTECH also has an ongoing Phase 1 clinical study of eryaspase in the United States in adults with newly diagnosed ALL and a Phase 2b clinical study in Europe in elderly patients with newly diagnosed acute myeloid leukemia (AML), each in combination with chemotherapy.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Contact information

ERYTECH
Naomi Eichenbaum, + 1 917-312-5151
Director of Investor Relations
naomi.eichenbaum@erytech.com
or
The Ruth Group
Media Relations
Kirsten Thomas, +1 508-280-6592
kthomas@theruthgroup.com
or
NewCap
Julien Perez, +33 1 44 71 98 52
Investor Relations
or
Nicolas Merigeau, +33 1 44 71 98 52
Media Relations
erytech@newcap.eu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

düber Technologies Inc. Secures Funding for 15 Distribution Centers with $50 Million Agreement with Vacone Real Estate26.9.2017 23:59Tiedote

düber Technologies Inc., a software-as-a-service (SaaS) provider serving the cannabis industry, today announced it has signed a $50 million funding agreement with Vacone Real Estate for the acquisition, fit out and master lease for 15 cannabis distribution centers in Washington, Oregon, California, Nevada and Arizona. The deal will allow düber to expand operations to include 400,000 square feet of distribution space that will form the basis of the düber unified distribution technology platform. “At düber, we see an unmet market opportunity for cannabis producers, processors and retailers in key parts of the country,” said Glenn Ballman, founder of düber. “This expansion will allow us to serve our distribution and courier partners while continuing to expand our integrated, omnichannel, real-time platform to partners and consumers in key markets in the cannabis industry

Piraeus Bank Comments on Bank of Greece Audit26.9.2017 19:20Tiedote

In response to a query by the Hellenic Capital Markets Committee, Piraeus Bank notifies the investment community that, on 19 September 2017 and following our prior announcement regarding the same matter, we received a draft report for an audit conducted by the Bank of Greece in the course of an Annual Audit Plan. The audit commenced in February 2017, was concluded in July 2017, and focused on a review of the Bank’s procedures for the implementation of the regulatory framework, as well as risk management procedures and special credit issues. Piraeus Bank cooperated fully and constructively with the Bank of Greece during the audit process. Piraeus Bank will respond to the Bank of Greece within a specific timeline and the final report from the Bank of Greece is expected to follow. Piraeus Bank considers that the historic issues covered by the Bank o

Oxera Releases New Analysis on Europe’s Aviation Market, Revealing Increased Competition between Airports26.9.2017 19:13Tiedote

Oxera Consulting LLP has revisited the subject of airport competition in Europe, conducting research and analysis on the implications of recent market trends on the dynamics between airports and airlines in Europe. Oxera found that the European aviation market grew by 25% between 2010 and 2016, with key trends including the continuing rapid expansion of LCCs (low-cost carriers) and non-traditional hubs in the Middle East and Istanbul. These developments have contributed to an intensification of the rivalry between airports, across all channels through which they compete. With many of these trends now being long established, the competitive pressures on airports, of all sizes, across Europe are highly likely to endure and continue to develop, implying that regulators and government stakeholders will need to address this ‘new normal’. Andrew Meaney, Partner and H

RHÖN-KLINIKUM AG Diligently Presses Ahead with Digitalization26.9.2017 18:29Tiedote

RHÖN-KLINIKUM AG is forging ahead with the implementation of its digitalization strategy and is launching a new collaboration with Austrian enterprise search and big data provider Mindbreeze, a subsidiary of the publicly listed Fabasoft AG. The clinic group will use Mindbreeze’s AI-based (artificial intelligence) search engine technology. With this application ─ in the form of a medical cockpit ─ that has been further developed in close cooperation with RHÖN-KLINIKUM AG, the entire medical staff can orient themselves more quickly and their workload is immediately alleviated. “This new approach to medical information will help us to structure the increasing amount of data and then make the information analyzable and evaluable. This is another aspect in which digitalization presents a tangible, concrete benefit,” says Stephan Holzinger, CEO of the group. The medical cockpit is initially being

Before the winter season, Mytyres.co.uk presents: Europe’s most popular summer tyres in 201726.9.2017 18:14Tiedote

In 2017, Europe’s most popular summer tyres were the Continental PremiumContact 6, the Uniroyal Rainsport 3, and the Dunlop SportMaxx RT2. This is the result of a survey conducted by Mytyres.co.uk, the end-user online shop for tyres, car spare parts and accessories from Europe's largest Internet tyre wholesaler Delticom. The survey was conducted throughout July and August in twelve European countries. Nearly 2,600 visitors to the online store cast their votes before the end of the summer tyre season. They were able to choose from five models by leading brands. “Interestingly, the results show that throughout Europe, high-quality premium brand models are the most popular”, comments Thierry Delesalle from Mytyres.co.uk. “These brands rightly enjoy a good reputation, but these days attractive alternatives are also available in the low-cost quality tyre segment. This also applies to

Quadient Launches Alliances and ISV/Technology Partner Tracks of Partner Advantage Program26.9.2017 17:30Tiedote

www.quadient.com : Quadient, formerly GMC Software, the award-winning leader in Customer Communications Management (CCM), announced today the launch of the Alliances Partner and ISV/Technology Partner tracks of its Partner Advantage Program intended to engage, empower and enable all types of Quadient partners. The two tracks complete the four-track program, which began with the announcement in April 2017 of the Delivery Partner track, designed to provide seamless implementation services for Quadient’s customer base. It was followed by the launch of the Business Partner track in May 2017, which offers technology service providers access to new revenue opportunities. Companies approved to become certified Alliances Partners are system integrators/consultants that deliver services, implement and support the Quadient solutions they recommend to their customers. ISV/Technolo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme